Solara Active Pharma Sciences reported a strong turnaround in Q2 FY27, posting a net profit of Rs 28.5 crore against a loss in the previous year. Revenue climbed 33% to Rs 418 crore, while EBITDA margin expanded to 18.4%. Driven by disciplined cost management and a 37% surge in base business revenue, the company also successfully reduced net debt to Rs 500 crore. Management is now evaluating strategic options for its Ibuprofen business and Vizag facility, with a decision expected within 12 weeks.
Solara Active Pharma Reports Q2 Profit of Rs 28.5 Crore
Revenue grew 33% to Rs 418 crore, while EBITDA surged 118% to Rs 77 crore.
Reader Takeaway: Strong operational turnaround and debt reduction drive performance, but strategic clarity on Ibuprofen unit remains vital.
What just happened
Solara Active Pharma Sciences announced a significant turnaround in its Q2 FY27 financial results. The company shifted from a loss-making position to a net profit of Rs 28.5 crore, supported by a 33% jump in consolidated revenue to Rs 418 crore. EBITDA margins showed substantial improvement, rising to 18.4% compared to 11% in the corresponding quarter last year.
Why this matters
The company’s performance highlights the success of its ongoing operational discipline and cost-leverage strategies. A critical development is the reduction of net debt to Rs 500 crore, down from Rs 614 crore in March 2026. This has significantly improved the net debt-to-EBITDA ratio to 1.8x on an H1 annualized basis, providing much-needed balance sheet stability for shareholders.
Business and Operational Updates
The Ibuprofen segment, a significant focus area, reported revenue of Rs 91 crore, reflecting an 18% quarter-on-quarter growth. While the segment is approaching breakeven, management is conducting a strategic review of this business and the Vizag facility to optimize operations. A final decision on these assets is anticipated within the next 12 weeks.
Risks to watch
Despite the positive momentum, several challenges remain. The ongoing West Asia crisis is creating intermittent logistics bottlenecks and impacting raw material availability and pricing. Trade receivables also remain a key focus area due to the nature of billing cycles. Additionally, the outcome of the strategic review for the Ibuprofen segment and the Vizag facility will be a major market catalyst in the near term.
What to track next
Investors should closely monitor the 12-week timeline for the company’s strategic announcements regarding its business units. Sustaining margin improvements while managing geopolitical supply-chain pressures will be the primary test for the company in the coming quarters.